Clinical Trials Logo
  1. Home
  2. Adenocarcinoma of Lung
  3. NCT02493582

The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR

Adenocarcinoma of Lung Clinical Trial

Official title:
The Randomized, Controlled Clinical Trial of Apatinib Plus CIK as the Third Line Therapy for Lung Adenocarcinoma Patients With Wild-Type EGFR

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of Apatinib combined with cytokine-induced killer cell (CIK) vs Apatinib alone as the third line therapy for advanced lung adenocarcinoma patients with wild-type EGFR

Clinical Trial Description

400 patients with stage IIIB & IV lung adenocarcinoma who had received surgery and chemotherapy,will be randomly divided into group A（Apatinib plus CIK treatment ) or group B（Apatinib), and the randomize ratio will be 1:1. Patients in group A will receive 3 cycles of CIK treatment (every 1 year) and Apatinib (continuous).Patients in group B will receive only Apatinib (continuous) . ;

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02493582
Study type Interventional
Source The First People's Hospital of Changzhou
Contact
Status Active, not recruiting
Phase Phase 2
Start date July 2015
Completion date July 2033
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04122833 - Impact of Concomitant Genetic Alterations in EGFR Mutated Adenocarcinoma by NGS Analysis: A Multicenter Study
Recruiting NCT04557449 - Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors Phase 1/Phase 2
Terminated NCT04027946 - LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Phase 2
Not yet recruiting NCT05079022 - ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas Phase 1/Phase 2
Completed NCT02616211 - An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors
Completed NCT03184571 - Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC Phase 2
Recruiting NCT05550961 - APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Therapies: Real World Data and Translational Reaserch
Active, not recruiting NCT05292859 - Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs
Not yet recruiting NCT05565677 - Prognostic Value of Lung Cancer MicroAnatomy in 3D
Completed NCT05252676 - Evaluation of Correlations Between Radiologic Features and Pathologic Subtypes of GGO LUAD Via WMS (ECTOP-1011)
Recruiting NCT03838588 - The Tracking Molecular Evolution for NSCLC (T-MENC) Study
Recruiting NCT04105270 - RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial Phase 2
Not yet recruiting NCT02946216 - ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC N/A
Completed NCT00073398 - Vaccine Treatment for Advanced Non-Small Cell Lung Cancer Phase 1/Phase 2
Recruiting NCT04770688 - Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib Phase 1/Phase 2
Completed NCT04165759 - HRCT in Prediction of Tumor Invasion in GGO Lung Adenocarcinoma (ECTOP-1008)
Completed NCT04086680 - The Detection of EGFR Mutations in Liquid Based Cytology Samples
Completed NCT01362790 - SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma Phase 1/Phase 2
Recruiting NCT06299163 - NM32-2668 in Adult Patients With Selected Advanced Solid Tumors Phase 1
Recruiting NCT03298763 - Targeted Stem Cells Expressing TRAIL as a Therapy for Lung Cancer Phase 1/Phase 2